An Open-Label Rollover Study of PBI 4050 in Subjects With Alstrom Syndrome

Trial Profile

An Open-Label Rollover Study of PBI 4050 in Subjects With Alstrom Syndrome

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs PBI 4050 (Primary)
  • Indications Alstrom's Syndrome
  • Focus Adverse reactions; Registrational
  • Sponsors ProMetic Biosciences
  • Most Recent Events

    • 14 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top